.jpg)
.png)
Top Stories
The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015. Led by Editor-In-Chief W. Virgil Brown, M.D., the JCL has seen a steady growth in submissions and readership since first publishing in 2007. It now ranks 17th of 256 journals in... more
On February 28, 2012, the Food and Drug Administration (FDA) approved crucial changes to the safety label for statins. The changes are based upon the FDA's further review of the data and are as follows: Removing the recommendation for periodic monitoring of liver enzymes; Adding a warning... more
Expert Panel Re-affirms the Importance of Setting Cholesterol Goals for the Prevention of Heart Attack and Stroke NEW YORK (Sept. 15, 2014) — Today, the National Lipid Association (NLA) released new recommendations based on a panel of independent experts, published in the Journal of... more
December 18, 2018 Melissa Goetz Lindsey Sutton Co-Presidents Familial Chylomicronemia Syndrome Foundation 7523 Rowena St San Diego, CA 92119 An Open Letter to Familial Chylomicronemia Syndrome... more
Experiencing side effects such as muscle-related pain or weakness was the top reason why patients stopped taking statins, according to results from a large survey. MedPage Today - June 22, 2012
Pursuant to the advice of the Chapter of the National Lipid Association, the following updates to the Bylaws are proposed to the NLA membership for adoption at the NLA Business Meeting on May 18, 2019. The purpose of the update is to restore the position of the at-large directors on the chapter... more
On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under... more
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical... more
JACKSONVILLE, Fla. (April 12, 2019) — The 2019 National Lipid Association Nominating Committee released its annual report and recommendations on Monday. Chaired by NLA Immediate Past President James A. Underberg, MD, MS, FNLA, the committee compiled a list of recommended candidates to... more
Following an October 2012 recommendation by the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved lomitapide for patients with homozygous FH. Lomitapide, known by the brand name Juxtapid, is produced by Aegerion Pharmaceuticals. Results from the company... more